Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Photo Illustration: Joe Raedle/Getty Images
More than 400 patients in 45 states have reported problems filling their EpiPen subscriptions amid issues with the manufacturing of the automatic injector, Bloomberg reports.
The backdrop: The U.S. Food and Drug Administration warned Meridian Medical Technologies Inc., the unit of Pfizer that manufactures EpiPens, last September about its failures to thoroughly look in to product mishaps, including EpiPen products linked to severe illnesses and patient deaths. A Pfizer spokesman told Bloomberg that a new processes in response the FDA’s warning had caused manufacturing delays.